HJ445A is a potent MYOF inhibitor that binds to the MYOF-C2D domain with a KD of 0.17 μM; it exhibits significant anti-proliferative effects against gastric cancer cells (IC50 = 0.16 μM for MGC803 and 0.14 μM for MKN45); it demonstrates excellent in vivo antitumor efficacy and can be used in cancer research.